weight loss
∙3 minute read
As you may be aware, Eli Lilly has announced a UK price increase on Mounjaro. We know changes like this can be unsettling. Our priority is safe, continuous care - keeping you informed, helping you weigh up your options, and supporting whatever decision you make.
The price change affects Mounjaro only. Wegovy and our other weight loss treatments are not impacted.
Eli Lilly is aligning UK pricing with the rest of the world - this isn’t due to supply issues or provider costs.
We’re working on additional support for existing patients and will share details soon.
You can continue with your current plan, make an adjustment, or switch treatments if appropriate. We’ll help you choose the approach that fits your goals and budget.
Options include:
Staying on your current Mounjaro dose.
Reducing your Mounjaro dose to manage cost and side effects.
Switching from Mounjaro to Wegovy.
Pausing medication and continuing with behavioural/lifestyle changes.
If you’d like to switch, submit a request in the app or complete the short form. A Numan clinician will review your details and confirm next steps by email.
Mounjaro activates two hormone pathways (GIP and GLP-1), while Wegovy activates GLP-1 only. Both are weekly injections.
Wegovy is a proven, effective weight-loss treatment: pivotal trials showed average weight loss of around 15% at 68 weeks when combined with lifestyle changes.1 Individual results vary, and ongoing lifestyle support remains key with any medicine.
Most people won’t need a “washout” period. In general, we advise starting Wegovy one week after your last Mounjaro injection to keep a steady weekly rhythm.2 Always follow the plan your clinician has prescribed for you.
Submit your request in the app or here.
A clinician will confirm whether switching is safe and appropriate, advise your start date, and set your dose plan.
Take your first Wegovy dose on the advised day (usually 7 days after your last Mounjaro dose). Track progress in the app and message us anytime for support.
Weight loss medications can be powerful tools, but they don’t replace the foundations: how you eat, move, sleep, and cope with stress. Those everyday choices are what protect your progress for the long term - during treatment and after.
Your coaching tools continue as usual, and if you choose to stop medication, you’ll keep access to coaching for 3 months after your last delivery. You can also message your health coach or clinician for personalised guidance.
Price changes might bring uncertainty, but Numan’s commitment to your health stays the same. Whether you stay on Mounjaro, adjust your dose, or switch to Wegovy, we’ll keep your plan safe, transparent, and tailored to you.
Note: This article provides general information and isn’t a substitute for individual medical advice. A Numan clinician will review your request and confirm the safest plan for you.
1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., … STEP 1 Study Group. (2021). Once-weekly semaglutide in adults with overweight or obesity. The New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183
2. Jain, A. B., Ali, A., Gorgojo Martínez, J. J., Hramiak, I., Kavia, K., Madsbad, S., … Vilsbøll, T. (2021). Switching between GLP‐1 receptor agonists in clinical practice: Expert consensus and practical guidance. International Journal of Clinical Practice, 75(2). doi:10.1111/ijcp.13731
Written by Dr Luke Pratsides
Head of Clinical Governance, MBBS, MSc, MRCGP, MFCI
